MedKoo Biosciences

Naloxegol Free Base
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414430

CAS#: 854601-70-0 (free base)

Description: Naloxegol Free Base is a peripherally acting opioid receptor antagonist specific for mu-opioid receptors. Used to decrease the constipating effects of opioids.

Chemical Structure

Naloxegol Free Base

CAS# 854601-70-0 (free base)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 414430
Name: Naloxegol Free Base
CAS#: 854601-70-0 (free base)
Chemical Formula: C34H53NO11
Exact Mass: 651.36
Molecular Weight: 651.794
Elemental Analysis: C, 62.65; H, 8.20; N, 2.15; O, 27.00

Price and Availability

Size	Price	Availability
1mg	USD 305	2 Weeks
2mg	USD 490	2 Weeks
5mg	USD 800	2 Weeks
10mg	USD 1100	2 Weeks
25mg	USD 1950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 854601-70-0 (free base); 1354744-91-4 (oxalate)

Synonym: Naloxegol Free Base; NKTR118; NKTR-118; NKTR 118; HSDB8338; HSDB-8338; HSDB 8338

IUPAC/Chemical Name: Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)-

InChi Key: XNKCCCKFOQNXKV-YZHZYEHBSA-N

InChi Code: InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29-,32+,33+,34-/m1/s1

SMILES Code: OC1=CC=C2C[C@@H](N(CC=C)CC3)[C@]4(O)CC[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)[C@@]5([H])[C@]43C2=C1O5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Naloxegol Free Base is a peripherally acting opioid receptor antagonist specific for mu-opioid receptors.
In vitro activity:	At the human µ-opioid receptor in vitro, naloxegol was a potent inhibitor of binding (Ki = 7.42 nM) and a neutral competitive antagonist (pA2 - 7.95); agonist effects were <10% up to 30 μM and identical to those of naloxone. Reference: J Pharmacol Exp Ther. 2017 May;361(2):280-291. https://pubmed.ncbi.nlm.nih.gov/28336575/
In vivo activity:	TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 651.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther. 2017 May;361(2):280-291. doi: 10.1124/jpet.116.239061. Epub 2017 Mar 23. PMID: 28336575; PMCID: PMC5399635.
In vitro protocol:	Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther. 2017 May;361(2):280-291. doi: 10.1124/jpet.116.239061. Epub 2017 Mar 23. PMID: 28336575; PMCID: PMC5399635.
In vivo protocol:	TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4. PMID: 24896818.

2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Naloxegol. 2020 Mar 24. PMID: 31643924.

3: Daniali M, Nikfar S, Abdollahi M. Evaluating naloxegol for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2020 Jun;21(8):883-891. doi: 10.1080/14656566.2020.1735354. Epub 2020 Mar 4. PMID: 32129103.

4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Naloxegol. 2019 Jun 3. PMID: 31260226.

5: Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. Clin Pharmacokinet. 2017 Jun;56(6):573-582. doi: 10.1007/s40262-016-0479-z. PMID: 28035588.

6: Leppert W, Woron J. The role of naloxegol in the management of opioid-induced bowel dysfunction. Therap Adv Gastroenterol. 2016 Sep;9(5):736-46. doi: 10.1177/1756283X16648869. Epub 2016 May 26. PMID: 27582887; PMCID: PMC4984326.

7: Davies AN, Leach C. Naloxegol for opioid-induced sphincter of Oddi spasm/dysfunction. BMJ Support Palliat Care. 2019 Dec;9(4):365-366. doi: 10.1136/bmjspcare-2019-001808. Epub 2019 Jun 14. PMID: 31201151.

8: Al-Huniti N, Zhou D, Xu H, Aksenov S, Bui KH, Fox R, Helmlinger G, Stanski D. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label. Clin Pharmacol Ther. 2017 Nov;102(5):741-744. doi: 10.1002/cpt.719. Epub 2017 May 26. PMID: 28548207.

9: ▼Naloxegol for opioid-induced constipation. Drug Ther Bull. 2015 Dec;53(12):138-40. doi: 10.1136/dtb.2015.12.0369. PMID: 26660436.

10: Tack J, Corsetti M. Naloxegol for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):855-61. doi: 10.1586/17474124.2014.939629. Epub 2014 Sep 15. PMID: 25220391.

Your view history

Naloxegol Free Base featured